Wolverine Trading
CHRS icon

Wolverine Trading’s Coherus Oncology CHRS Stock Holding History

Wolverine Trading’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,100
Closed -$38.5K – 4548
2024
Q1 		$38.5K Sell
16,100
-700
-4% -$1.72K ﹤0.01% 4263
2023
Q4 		$55.9K Sell
16,800
-11,800
-41% -$31.6K ﹤0.01% 4230
2023
Q3 		$107K Buy
28,600
+8,900
+45% +$41.1K ﹤0.01% 3979
2023
Q2 		$82.5K Buy
+19,700
New +$116K ﹤0.01% 3829
2023
Q1 		– Sell
-17,000
Closed -$135K – 4298
2022
Q4 		$135K Buy
+17,000
New +$131K ﹤0.01% 3312
2021
Q3 		– Sell
-12,800
Closed -$180K – 6311
2021
Q2 		$180K Buy
12,800
+1,500
+13% +$21.2K ﹤0.01% 5084
2021
Q1 		$163K Buy
+11,300
New +$192K ﹤0.01% 5192
2020
Q4 		– Sell
-20,900
Closed -$393K – 4854
2020
Q3 		$393K Buy
+20,900
New +$389K ﹤0.01% 3073
2020
Q1 		– Sell
-29,000
Closed -$509K – 4682
2019
Q4 		$509K Buy
+29,000
New +$535K ﹤0.01% 3050
2017
Q4 		– Sell
-14,400
Closed -$192K – 4978
2017
Q3 		$192K Sell
14,400
-32,300
-69% -$427K ﹤0.01% 3834
2017
Q2 		$675K Buy
+46,700
New +$898K ﹤0.01% 2133
2017
Q1 		– Sell
-8,900
Closed -$251K – 4321
2016
Q4 		$251K Buy
+8,900
New +$249K ﹤0.01% 3456

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wolverine Trading's CHRS Position: Q3 2025 in Review

Wolverine Trading increased its Coherus Oncology (CHRS) stake by 71% in Q3 2025, buying an estimated $14.1K and bringing the position to 30,360 shares worth $51.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5405.

Wolverine Trading first reported a position in CHRS in Q2 2017 and has held it in 11 quarters since. The position peaked at $367K in Q4 2019. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Wolverine Trading held 30,360 shares of Coherus Oncology worth $51.6K as of Q3 2025.
  • Wolverine Trading bought 12,657 Coherus Oncology shares in Q3 2025, an estimated $14.1K.
  • Coherus Oncology made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5405 holding.
  • Wolverine Trading first reported a position in Coherus Oncology in Q2 2017 and has held it in 11 quarters since.
  • Wolverine Trading's Coherus Oncology position peaked at $367K in Q4 2019.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.